Pharmacokinetics and Pharmacodynamics Assessment of Drug Eritromax Compared to Eprex in Healthy Subjects.

Exclusion Criteria

• •Participation in clinical trials in the 12 months preceding the survey;
• •Presence of iron deficiency anemia;
• •Presence of pulmonary diseases, cardiovascular, neurological, endocrine, gastrointestinal, genitourinary or other systems;
• •Acute disease in the period of 07 days prior to inclusion;
• •Chronic administration of medication to determine, such as high blood pressure;
• •Hormone therapy in the period of 02 months prior to inclusion;
• •Administration of any drug in the 02 weeks prior to inclusion;
• •A history of autoimmune anemia or hereditary;
• •research subjects with a history of chronic bleeding;
• •research subjects with a history of acute bleeding in the last 30 days;
• •History of sensitivity to biological products derived from mammals, albumin, or any component of the formulation;
• •History of or current use at least 12 months of tobacco;
• •Current or previous history (less than 12 months) of illicit drug use;
• •previous therapy with erythropoietin;
• •albumin below 3.5 g / dl or greater than 4.8 g / dL;
• •Signs or clinical history of bone marrow aplasia;
• •History of liver disease and clinical or laboratory;
• •History of renal disease and clinical or laboratory.